• Skip to primary navigation
  • Skip to main content

Convergence Healthcare Advisors

Bulge Bracket Expertise, Boutique Bank Environment

  • Home
  • Team
  • Services
  • Experience
  • News
  • Contact
You are here: Home / Transactions / Lumora, Inc. Sale of Heat Elution Sample Prep Technology to Roche
Lumora

Lumora, Inc.

Sale of Heat Elution Sample Prep Technology and Intellectual Property

Roche

Terms: Not Disclosed
Date Announced: August 2015

Lumora is a UK-based leading developer of next-generation solutions in Molecular Diagnostics products and solutions. Lumora developed a highly differentiated proprietary methodology that will enable simple and automated nucleic acid isolation in minutes instead of hours called Heat Elution. The technology is environmentally friendly and can be applied to process a wide variety of sample types including whole blood, fecal matter, sputum, FFPE tissue and buccal swabs.

Convergence had been engaged by Lumora’s Board of Directors to help the Company assess strategic alternatives for the Company. Working with the senior team at Lumora, including CEO and Founder Laurence Tisi and Commercial Director Hayden Jeffreys, Convergence identified Heat Elution as a unique, value-added technology for Nucleic Acid Extraction that could be specifically interesting to companies competing in the sequencing sector given its workflow advantages. As part of this process, Convergence provided strategic advice regarding process, structure and valuation as Lumora pursued a sale of Heat Elution to Roche, and then a subsequent sale of the company.

The principals of Convergence Healthcare Advisors LLC and Seven Hills Healthcare Advisors LLC are licensed investment banking agents, offering securities through M&A Securities Group, Inc., an unaffiliated broker-dealer. Member FINRA/SIPC. 4151 N. Mulberry Drive, Suite 252 Kansas City, MO 64116.

© 2023 Convergence Healthcare Advisors · Built on the Genesis Framework by AMN Design · Powered by WordPress

Legal Disclosures